At identical concentrations and exposure times the Mirk kinase inhibitor RO5454948 was toxic to ovarian cancer cells with low or absent expression of the CDK inhibitors p16 and p21, the latter because of mutated, inactivated p53, a mutation seen in almost all ovarian cancers. Here, TP53 is linked to ovarian carcinoma.